The proposed mechanistic outcome of D3 and L3 activation on melanoma development and therapy through activation of classical, VDR, and non-canonical (AhR, RORs, LXRs, PPARγ) nuclear receptors is presented in Figure 5. The gene discussed is VDR; the disease is melanoma.